false2025Q2--12-310001944885June 30, 20250001944885ifrs-full:TopOfRangeMember2025-01-012025-06-300001944885aplm:InitialSupplyOfDrugProductMember2025-01-012025-06-300001944885aplm:LicensePerformanceObligationMember2025-01-012025-06-300001944885aplm:ClassAOrdinarySharesMemberaplm:TwoThousandAndTwentyThreeIncentiveAwardPlanMember2025-06-300001944885ifrs-full:PreferenceSharesMember2023-12-310001944885ifrs-full:RetainedEarningsMember2024-01-012024-06-300001944885aplm:ClassBOrdinarySharesMember2025-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2023-12-310001944885aplm:ProjectMaxSpacMergerSubIncMember2025-01-012025-06-300001944885ifrs-full:IssuedCapitalMember2025-06-300001944885aplm:SubsequentEventsMember2025-10-012025-10-310001944885aplm:SettlementAgreementMember2025-01-012025-06-3000019448852025-01-012025-06-300001944885aplm:PennyWarrantsMemberaplm:PipeSubscriptionAgreementMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001944885ifrs-full:TopOfRangeMember2024-06-300001944885ifrs-full:BottomOfRangeMember2024-06-300001944885ifrs-full:PreferenceSharesMember2024-12-310001944885ifrs-full:SharePremiumMember2025-06-300001944885ifrs-full:RetainedEarningsMember2024-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2025-01-012025-06-3000019448852023-12-310001944885ifrs-full:BottomOfRangeMemberaplm:TwoThousandAndSixteenPlanMember2025-01-012025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2025-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2024-12-310001944885aplm:PipeSubscriptionAgreementMember2025-09-020001944885ifrs-full:GrossCarryingAmountMember2024-12-310001944885aplm:ClassAOrdinarySharesMember2025-06-300001944885country:CN2025-06-300001944885ifrs-full:IssuedCapitalMember2023-12-310001944885ifrs-full:SharePremiumMember2024-12-310001944885ifrs-full:IssuedCapitalMember2024-01-012024-06-300001944885ifrs-full:TopOfRangeMemberaplm:TwoThousandAndSixteenPlanMember2025-01-012025-06-300001944885aplm:LaunXPInternationalMember2025-03-012025-03-310001944885ifrs-full:SharePremiumMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMember2024-01-012024-06-300001944885aplm:ZhejiangCrownBochuangBiopharmaCoLtdMember2025-01-012025-06-300001944885aplm:LessThanOneYearMember2025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2024-01-012024-06-300001944885ifrs-full:ShareOptionsMember2024-01-012024-06-300001944885ifrs-full:IssuedCapitalMember2024-06-300001944885aplm:LicensePerformanceObligationMember2025-06-3000019448852024-12-310001944885aplm:PennyWarrantsMemberaplm:PipeSubscriptionAgreementMemberifrs-full:Level3OfFairValueHierarchyMember2025-01-012025-06-300001944885ifrs-full:IssuedCapitalMember2025-01-012025-06-300001944885ifrs-full:OrdinarySharesMember2024-06-300001944885aplm:TwoThousandAndSixteenPlanMemberaplm:RestrictedShareAwardsMember2025-01-012025-06-300001944885ifrs-full:RetainedEarningsMember2025-06-300001944885ifrs-full:TopOfRangeMember2025-06-300001944885ifrs-full:PreferenceSharesMember2025-06-300001944885ifrs-full:RetainedEarningsMember2024-12-3100019448852025-06-300001944885aplm:TimeBasedShareOptionsMemberaplm:TwoThousandAndSixteenPlanMember2025-01-012025-06-300001944885aplm:PrivateWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001944885ifrs-full:OrdinarySharesMember2023-12-310001944885aplm:TwoThousandAndSixteenPlanMember2024-06-300001944885aplm:PublicWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001944885aplm:PublicWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level1OfFairValueHierarchyMember2025-01-012025-06-300001944885ifrs-full:BottomOfRangeMemberaplm:TwoThousandAndSixteenPlanMember2025-06-300001944885ifrs-full:OrdinarySharesMember2024-12-310001944885ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-12-310001944885aplm:PennyWarrantsMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMemberaplm:ShareAppreciationRightsrestrictedShareUnitAwardsAndOtherAwardsMember2025-01-012025-06-300001944885aplm:ApollomicsIncMember2025-01-012025-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMember2025-06-300001944885aplm:UnvestedRestrictedSharesMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMember2024-12-310001944885aplm:ApollomicsHongKongLimitedMember2025-01-012025-06-300001944885aplm:ApollomicsAustraliaPtyLtdMember2025-01-012025-06-3000019448852024-06-300001944885country:CN2024-12-310001944885aplm:PublicWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level1OfFairValueHierarchyMember2025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2024-12-310001944885aplm:LaunXPInternationalMember2025-01-012025-06-300001944885ifrs-full:TopOfRangeMemberaplm:TwoThousandAndSixteenPlanMember2025-06-300001944885aplm:ClassBOrdinarySharesMember2024-12-3100019448852024-01-012024-06-300001944885ifrs-full:GrossCarryingAmountMember2025-06-300001944885aplm:ApollomicsPrivateWarrantsMember2025-01-012025-06-300001944885aplm:TwoThousandAndSixteenPlanMemberaplm:RestrictedShareAwardsMember2024-01-012024-06-300001944885aplm:ClassBOrdinarySharesMember2023-12-310001944885aplm:SettlementAgreementMemberaplm:SubsequentEventsMember2025-11-192025-11-190001944885aplm:ApollomicsPublicWarrantsMember2024-01-012024-06-300001944885aplm:ClassAOrdinarySharesMember2024-06-300001944885aplm:ClassAOrdinarySharesMember2025-01-012025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2025-01-012025-06-300001944885ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2025-06-300001944885aplm:ApollomicsPrivateWarrantsMember2024-01-012024-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2024-06-300001944885ifrs-full:ShareOptionsMember2025-01-012025-06-300001944885ifrs-full:BottomOfRangeMember2025-01-012025-06-300001944885aplm:PipeSubscriptionAgreementMember2025-09-022025-09-020001944885ifrs-full:BottomOfRangeMember2025-06-300001944885aplm:PennyWarrantsMember2025-01-012025-06-300001944885ifrs-full:RetainedEarningsMember2023-12-310001944885aplm:ClassAOrdinarySharesMember2023-12-310001944885aplm:TwoThousandAndSixteenPlanMemberaplm:ShareAppreciationRightsrestrictedShareUnitAwardsAndOtherAwardsMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMemberaplm:RestrictedShareAwardsMember2025-06-300001944885aplm:InitialSupplyOfDrugProductMember2025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2024-06-300001944885aplm:UnvestedRestrictedSharesMember2025-01-012025-06-300001944885aplm:OtherReserveExcluedingShareBasedPaymentReserveMember2024-12-310001944885aplm:ClassAOrdinarySharesMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMemberifrs-full:ShareOptionsMember2025-01-012025-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2025-06-300001944885aplm:OneToTwoYearsMember2025-06-300001944885aplm:ZhejiangCrownmabBiotechCoLtdMember2025-01-012025-06-300001944885aplm:OtherReserveExcluedingShareBasedPaymentReserveMember2024-06-300001944885aplm:ClassAOrdinarySharesMemberaplm:PipeSubscriptionAgreementMember2025-09-020001944885aplm:ThreeToFiveYearsMember2025-06-300001944885aplm:ApollomicsPublicWarrantsMember2025-01-012025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2023-12-310001944885aplm:TwoThousandAndSixteenPlanMember2025-01-012025-06-300001944885ifrs-full:RetainedEarningsMember2025-01-012025-06-300001944885aplm:ClassAOrdinarySharesMember2024-12-310001944885aplm:ClassBOrdinarySharesMember2024-06-300001944885ifrs-full:SharePremiumMember2024-06-300001944885aplm:PennyWarrantsMemberaplm:PipeSubscriptionAgreementMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001944885aplm:PrivateWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level2OfFairValueHierarchyMember2025-01-012025-06-300001944885aplm:OtherReserveExcluedingShareBasedPaymentReserveMember2023-12-310001944885aplm:SettlementAgreementMember2025-06-3000019448852024-11-142024-11-140001944885aplm:OtherReserveExcluedingShareBasedPaymentReserveMember2025-06-300001944885ifrs-full:IssuedCapitalMember2024-12-310001944885ifrs-full:SharePremiumMember2023-12-310001944885aplm:MoreThanFiveYearsMember2025-06-300001944885aplm:PrivateWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level2OfFairValueHierarchyMember2025-06-300001944885aplm:TwoThousandAndSixteenPlanMember2023-12-310001944885ifrs-full:PreferenceSharesMember2024-06-300001944885ifrs-full:OrdinarySharesMember2025-06-30xbrli:purexbrli:sharesaplm:PerformanceObligationsiso4217:USDutr:Yiso4217:USDxbrli:shares


OMB APPROVAL
OMB Number:		3235-0116
Expires:		December 31, 2026
Estimated average burden
hours per response		8.7

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the ~~Month~~month of ~~December~~April ~~2025~~2026.

Commission File Number: 001-41670

Apollomics Inc.

~~(Translation~~Not Applicable ~~of registrant’s name into English)~~

~~989~~(Translation E.of ~~Hillsdale~~registrant’s ~~Blvd.,~~name ~~Suite~~into ~~220~~English)

989 E. Hillsdale Blvd., Suite 220, Foster City, CACalifornia 94404

~~Telephone:~~ (~~650~~Address of principal executive office) ~~209-4055~~

~~(Address~~Indicate by check mark whether the registrant files or will file annual reports under cover of ~~principal~~Form 20-F ~~executive~~or ~~office)~~Form 40-F.

~~Indicate by check mark whether the registrant files or will file annual reports under cover of~~ ☒ Form 20-F or ☐ Form 40-F:

~~Form~~Entry ~~20-F~~into ☒a ~~Form~~Material ~~40-F~~Definitive ☐Agreement; Related Party Transaction

~~EXPLANATORY~~On ~~NOTE~~March 30, 2026, Apollomics Inc. (the “Company”) entered into a Convertible Promissory Note (the “Note”) with Mr. Hung-Wen (Howard) Chen, the Company’s Chairman and Chief Executive Officer. Pursuant to the Note, Mr. Chen provided an unsecured bridge loan to the Company in the principal amount of $2,000,000.

OnThe ~~December~~Note ~~22,~~bears ~~2025,~~no ~~Apollomics~~interest ~~Inc.~~ (~~the~~0% ~~“Company”~~per annum) ~~issued~~and ~~unaudited~~is ~~condensed~~unsecured. ~~consolidated~~The ~~interim~~principal ~~financial~~amount ~~statements~~will ~~for~~automatically ~~the~~convert ~~six~~into ~~months~~equity ~~ended~~securities ~~June~~of ~~30,~~the ~~2025~~Company ~~and~~upon the ~~management~~closing of the Company’s ~~discussion~~next ~~and~~equity ~~analysis~~financing ofthat ~~financial~~raises ~~condition~~aggregate ~~and~~gross ~~results~~proceeds of ~~operations~~not less than $10,000,000 (the “~~MD&A~~Next Equity Financing”). ~~for~~Upon such conversion, the ~~six~~conversion ~~months~~price ~~ended~~will ~~June~~be ~~30,~~equal ~~2025~~to 80% of the lowest per-share purchase price paid by investors in the Next Equity Financing. AIf ~~copy~~the Note is not converted prior to the eighteen-month anniversary of ~~such~~its ~~unaudited~~issuance ~~condensed~~(the ~~consolidated~~“Maturity ~~interim~~Date”), ~~financial~~the ~~statements~~Holder ismay ~~attached~~elect to ~~hereto~~convert asthe ~~Exhibit~~Note ~~99.1.~~into Class A ~~copy~~ordinary shares of the ~~MD&A~~Company isbased ~~attached~~on ~~hereto~~the asaverage ~~Exhibit~~closing 99price of the shares for the ten trading days immediately preceding the Maturity Date.2.

OnBecause ~~December~~Mr. Chen ~~22,~~is ~~2025,~~an ~~the~~executive ~~Company~~officer ~~issued~~and adirector ~~press~~of ~~release~~the inCompany, ~~which~~the issuance of the ~~Company~~Note ~~reported~~constitutes ~~its~~a ~~financial~~related-party ~~results~~transaction. ~~for~~The ~~the~~transaction was ~~six~~reviewed ~~months~~and ~~ended~~recommended ~~June~~by 30the Audit Committee, ~~2025.~~which Aconsists ~~copy~~entirely of ~~such~~independent ~~press~~directors, ~~release~~and iswas ~~furnished~~subsequently asapproved ~~Exhibit~~by 99the Board of Directors, with Mr.3 Chen ~~hereto~~abstaining from the vote.

The ~~information~~Company ~~furnished~~intends ~~in Exhibit 99.1 and Exhibit 99.2~~ to ~~this~~use ~~Report of Foreign Private Issuer on Form 6-K (this “Report”) shall be deemed to be filed with~~ the ~~Securities~~proceeds ~~and~~from ~~Exchange Commission and incorporated by reference into~~ the ~~Company’s~~Note ~~registration~~for ~~statements~~working oncapital ~~Form S-8 (File No. 333-272559)~~ and ~~Form~~general ~~F-3~~corporate ~~(File~~purposes ~~Nos. 333-278430, 333-278431 and 333-279549), and any related prospectuses, as such registration statements and prospectuses may be amended from time~~ to ~~time,~~support ~~and~~its toongoing beclinical ~~a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished~~operations.

~~APPLICATION~~The OFinformation ~~HOME~~contained ~~COUNTRY~~in ~~PRACTICE~~this ~~RULES~~Form 6-K is incorporated by reference into the Company’s registration statements under the Securities Act of 1933, as amended, including its registration statements on Form S-8 (File Nos. 333-272559 and 333-293148) and Form F-3 (File Nos. 333-278430, 333-278431, 333-279549, and 333-294154), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

~~The~~EXHIBIT ~~Company~~INDEX is a “foreign private issuer” (as such term is defined in Rule 3b-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) and the Company’s Class A ordinary shares, par value $0.01 per share (each a “Class A Ordinary Share”), and warrants are listed on the Nasdaq Capital Market. As a foreign private issuer, the Company is permitted under Nasdaq rules to follow home country governance practices instead of certain Nasdaq requirements pursuant to Nasdaq Rule 5615(a)(3). As disclosed in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission on April 3, 2025 (the “Annual Report”), the Company follows home country corporate governance practices instead of certain Nasdaq corporate governance requirements, as described in more detail therein. The Company has also informed Nasdaq that it intends to follow home country governance practices in lieu of shareholder approval requirements in Nasdaq Rule 5635, and that it will disclose in its annual report on Form 20-F for the fiscal year ended December 31, 2025 each requirement that it does not follow and describe the home country practices it follows in lieu of such requirements.

EXHIBIT INDEX


Exhibit No.		Description

10.1		Convertible Promissory Note, dated March 30, 2026, issued by Apollomics Inc. to Hung-Wen Chen

99.1		Press Release dated April 1, 2026

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Exhibit No.		Description
99.1		Unaudited Condensed Consolidated Interim Financial Statements for the Six Months Ended June 30, 2025 and 2024, and as of June 30, 2025 and December 31, 2024
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2025 and 2024
99.3		Press release dated December 22, 2025
101		Interactive Data File (formatted as Inline XBRL)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2 of 2

~~SIGNATURES~~SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Apollomics Inc.
Date: December 22, 2025	By:	/s/ Hung Wen (Howard) Chen
		Name	Hung Wen (Howard) Chen
		Title:	Chief Executive Officer

APOLLOMICS INC.

(Registrant)

Date April 1, 2026

/s/ Peter Lin

(Signature)*

Peter Lin, Chief Financial Officer

* Print the name and title under the signature of the signing officer.


.SEC 1815 (07-22)		Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

3 of 3

Filing Compare · Apollomics Inc.